TUSTIN, Calif., Oct. 6 /PRNewswire-FirstCall/ -- Radient Pharmaceuticals Corporation (NYSE - AMEX: RPC), a US-based pharmaceutical company, announced today through its wholly-owned subsidiary AMDL Diagnostics, Inc. (ADI), it has entered into a two-year distribution agreement with Tarom Applied Technologies Ltd. for the marketing and sales of its Onko-Sure(TM) in vitro diagnostic (IVD) cancer test. Tarom Applied Technologies Ltd. is an established, privately-owned distributor of products in the biomedical sector with more than 20 years of exclusive representation for OEM diagnostic systems and reagents, biotech and research products and veterinary systems. The company is the exclusive distributor to the Israeli market and sells outside of Israel to leading worldwide manufacturers in the diagnostic and biomedical fields. The company's customers include medical centers and hospitals, clinical laboratories, universities, Ministry of Health labs, and biotech and pharmaceutical companies. Tarom also works directly with the Israeli Ministry of Health on licensing issues and other related matters. Today's agreement marks the latest business milestone in the Radient Pharmaceuticals' commercialization strategy for Onko-Sure(TM) (previously marketed as AMDL-ELISA DR-70® IVD cancer test). Under the terms of the partnership agreement, Tarom will market and distribute Onko-Sure(TM) to medical centers, hospitals, clinical laboratories, university labs, and Ministry of Health labs throughout Israel. This includes implementing a marketing strategy to drive product awareness, engage heathcare decision makers and thought-leaders, lab directors, physicians, and patients and healthcare consumers throughout Israel. "We are pleased with the addition of Tarom Applied Technologies to Radient Pharmaceuticals' list of product distributors," commented Mr. Douglas MacLellan, Chairman and CEO of Radient Pharma. "Through this agreement we are entering a highly opportunistic market with one of the most proven distributors in this region. Tarom has the expertise to rapidly commercialize Onko-Sure(TM) over the course of a renewable two-year period. This supports Radient Pharmaceuticals' highest priority - to create significant value for our shareholders while providing a diagnostic solution and product leadership in what is one of the most critical areas of life sciences and healthcare - in vitro cancer diagnostics." With the exception of heart disease, cancer causes more deaths than any other medical condition in the world. According to the World Health Organization (WHO), cancer is rapidly becoming the leading cause of death worldwide and is expected to overtake heart disease by 2010. Onko-Sure(TM) is a simple, non-invasive IVD blood test used for the detection and/or monitoring of at least 14 different types of cancer. According to industry research firm Visiongain, "In vitro diagnostics constitute an important, growing healthcare industry and market and one that is increasingly biotechnological and closely aligned with pharma. We believe from 2009 onwards, worldwide investment in IVD testing will increase due to greater awareness of tests' availability and usefulness; more-widely applicable, accurate and usable tests emerging; and increasing appreciation of early diagnosis, both for patient quality of life and cost efficiencies." In 2008 the global IVD market generated sales of over $40 billion and Visiongain predicts the market will generate nearly $60 billion by 2014. Currently, Onko-Sure(TM) is used as an IVD pan cancer screening and monitoring tool in Taiwan, Korea, India, and Vietnam. It is a US FDA cleared IVD cancer test for the monitoring of colorectal cancer (CRC). The test is also approved by Health Canada for the detection and monitoring of lung cancer in Canada. For additional information on Radient Pharmaceuticals, please visit the Company's corporate Web site at http://www.radient-pharma.com/. For Investor Relations information contact Kristine Szarkowitz at or 1.206.310.5323. About Radient Pharmaceuticals: Headquartered in Tustin, California, is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. Forward Looking Statements: Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. DATASOURCE: Radient Pharmaceuticals Corporation CONTACT: Kristine Szarkowitz, Director-Investor Relations, Radient Pharma, +1-206-310-5323, Web Site: http://www.radient-pharma.com/

Copyright